Accessibility Menu
Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals(NASDAQ) AMPH

Market Cap$1.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+137%
5 Year+24%
1 Year-19%
1 Month+20%
Premium Feature
Moneyball Superscore
59/100
$23.84
+0.42%
+0.10Today
Amphastar Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 23.842026-09-03
Amphastar Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.96%USD 21.882026-08-27
1 month+19.8%USD 19.902026-08-04
3 month+20.77%USD 19.742026-06-05
Year to date-10.98%USD 26.782025-12-31
1 year-18.88%USD 29.392025-09-03
3 year-56.28%USD 54.532023-09-01
5 year+23.72%USD 19.272021-09-03
Since inception+137.16%USD 10.012014-06-26

Amphastar Pharmaceuticals Financials at a Glance

Market Cap

$1.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$730.02M

Net Income (TTM)

$78.55M

EPS (TTM)

$1.71

P/E Ratio

13.97

Dividend

$0.00

Beta (Volatility)

0.57 (Low)

Price

$23.84

Volume

469,751.871

Open

$23.88

Previous Close

$23.84

Daily Range

$23.04 - $23.92

52-Week Range

$16.65 - $29.78

Estimated Earnings Date

Nov 5, 2026

AMPH News

SellAlert-Red.png

Amphastar Director Sells 16,679 Shares for $441,800

Sarah SidlowDec 23, 2025
lab pharma microscope.jpg

Amphastar: Earnings Miss, Margins Drop

Motley Fool Markets TeamFeb 28, 2025
medstocks

Why Shares of Amphastar Pharmaceuticals Rose Today

James HalleyMar 1, 2023
Money falling from sky buyout takeover riches

Why Amphastar Pharmaceuticals, Inc. is Soaring Today

Brian FeroldiSep 20, 2016

AMPH: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. makes medicines for asthma and allergies. It makes inhalers and injections used in hospitals and at home. Its treatments help people manage chronic conditions and emergency health needs.

Medicines for Urgent Needs

  • Emergency Medicines: BAQSIMI nasal powder for low blood sugar and Glucagon kits.
  • Inhalation Products: Primatene Mist for asthma relief and Ipratropium Bromide for breathing issues.
  • Injectable Treatments: Epinephrine for severe allergies and Lidocaine for pain relief.
  • Ingredient Supply: Active Pharmaceutical Ingredients (API), which are the core chemicals used to produce finished medical drugs.

Strategic Deals and Product Launches

  • Acquired BAQSIMI from Eli Lilly & Company and reached $175.0 million in sales during the first contract year.
  • Launched Ipratropium Bromide HFA inhalation aerosol in April 2026 following FDA approval.
  • Introduced iron sucrose and teriparatide products in 2025 to expand the specialized injectable portfolio.
  • Released Albuterol in August 2024 to strengthen the inhalation product line.

Technical Focus and Global Reach

Manufacturing facilities in the United States, China, and France provide control over technical production processes. Internal research focuses on developing complex drug delivery systems like nasal sprays and pressurized metered-dose inhalers.

Key Financial Performance Data

  • Net revenues reached $183.9 million for the three-month period ended June 30, 2026, up 5% year over year.
  • Total net revenues for the six-month period ended June 30, 2026, reached $355.1 million, up 3% year over year.
  • Net income was $36.8 million for the six-month period ended June 30, 2026.
  • Working capital was $367.8 million as of June 30, 2026, compared to $477.9 million at Dec. 31, 2025.

The Path Forward

Amphastar has evolved from a generic drug manufacturer into a developer of complex proprietary medical treatments. This transition supports a portfolio of technically challenging products used in emergency and chronic healthcare settings.

AI Generated • Aug 7, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1,976

CEO

Yong Feng Zhang, PhD

Website

www.amphastar.com

Headquarters

Rancho Cucamonga, CA 91730, US

AMPH Financials

Key Financial Metrics (TTM)

Gross Margin

47.68%

Operating Margin

15.66%

Net Income Margin

10.76%

Return on Equity

10.11%

Return on Capital

9.72%

Return on Assets

4.50%

Earnings Yield

7.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

42.54M

Volume

469.75K

Avg. Volume

483.59K

Financials (TTM)

Gross Profit

$348.11M

Operating Income

$114.29M

EBITDA

$174.76M

Operating Cash Flow

$184.61M

Capital Expenditure

-$31.72M

Free Cash Flow

$152.89M

Cash & ST Invst.

$290.12M

Total Debt

$688.32M

Amphastar Pharmaceuticals Performance Analysis

Amphastar Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 498,987,00014.0%
20232023-12-31USD 644,395,00029.1%
20242024-12-31USD 731,967,00013.6%
20252025-12-31USD 719,887,000-1.7%
Amphastar Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3010.0%
Q42025-12-31-4.6%
Q12026-03-31-6.5%
Q22026-06-307.4%
Amphastar Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.7439.7%
20232023-12-31USD 2.6048.9%
20242024-12-31USD 3.0618.1%
20252025-12-31USD 2.03-33.6%
Amphastar Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-42.2%
Q42025-12-3137.8%
Q12026-03-31-72.5%
Q22026-06-30378.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$183.90M

+5.4%

Gross Profit

$93.47M

+8.1%

Gross Margin

50.83%

N/A

Market Cap

$1.01BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$513.21K

N/A

Employees

1,976

N/A

Net Income

$30.35M

-2.2%

EBITDA

$45.20M

-26.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$290.12M

+25.2%

Total Debt

$688.32M

+5.0%

Accounts Receivable

$144.86M

+7.6%

Inventory

$179.91M

-6.2%

Long Term Debt

$677.03M

+4.7%

Short Term Debt

$11.29M

+28.2%

Return on Assets

4.50%

N/A

Return on Invested Capital

7.72%

N/A

Free Cash Flow

$42.73M

+70.7%

Operating Cash Flow

$51.32M

+44.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PCRXPacira BioSciences, Inc.
$26.60+0.08%
COLLCollegium Pharmaceutical, Inc.
$23.70-2.47%
ANGOAngioDynamics, Inc.
$15.47-0.96%
ANIPANI Pharmaceuticals, Inc.
$71.99-1.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$106.74+0.00%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$51.60-0.00%
IBITiShares Bitcoin Trust
$46.35+0.06%

Questions About AMPH

What is the current price of Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals is trading at $23.84 per share.

What is the 52-week range for Amphastar Pharmaceuticals?

Over the past 52 weeks, Amphastar Pharmaceuticals has traded between $16.65 and $29.78.

How much debt does Amphastar Pharmaceuticals have?

As of the most recent reporting period, Amphastar Pharmaceuticals reported total debt of $688.32M.

How much cash does Amphastar Pharmaceuticals have on hand?

Amphastar Pharmaceuticals reported $223.85M in cash and cash equivalents in its most recent financial results.

What is Amphastar Pharmaceuticals’s dividend yield?

Amphastar Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services